Intracerebroventricular s tereptozotocin (STZ) treatment has been described as a suitable model for sporadic Alzheimer's disease (sAD). Centrally adminis tered STZ decreases insulin and insulin receptors in the brain and interrupts PI3/Akt signaling pathway and GSK-3β. Additionally it raises Bax/Bcl-2 ratio and prompts hippocampal apoptosis. Agmatine, a polyamine derived from L-arginine decarboxylation, is recently shown to exert some neuroprotective effects. This s tudy aimed to assess if agmatine reverses STZ-induced memory deficits and Akt/GSK-3β signaling disruption and apoptosis in the hippocampus. Adult male Sprague-Dawely rats weighing 200-250 g were used in this s tudy. The canules were implanted bilaterally into lateral ventricle. STZ was adminis tered on days 1 and 3 (3 mg/kg). Agmatine treatment (40 or 80 mg/kg) was s tarted from day 4 in an every other day manner and continued till day 14. The animal's learning and memory capability was assessed on days 15-18 using Morris water maze. After complement of the behavioral s tudies the hippocampi was isolated and the amounts of hippocampal cleaved caspase 3 (the landmark of apoptosis), Bax/Bcl-2 ratio, total and phosphorylated forms of GSK-3β and p-Akt were analyzed by wes tern blot.
